Fig. 7.

14–3-3η was involved in ATO-reversed MDR: The (a to c) scramble- or (d to f) 14–3-3η-siRNA transfected Bel/5-Fu cells were treated by different concentrations of 5-fluorouracil, oxaliplatin, and doxorubicin, in the absence of presence of 10 μM ATO for 24 h. The cell viability was determined in triplicate, and the IC50s were calculated